Abstract: An adjustable chair for patients undergoing dental procedures comprising a seat, back and leg rest. The seat is attached to a base with rotating adjustable members and a screw rod is used raise the seat from a lowered position of about 18 inches to a height of about 43 inches, thereby allowing the person performing the procedure to select either a seated or standing position. Further screw rod assemblies permit the back to recline to 15 to 30 degrees and the leg rest to raise to a level that is substantially parallel with the seat.

Abstract: A spine board is provided having a skull tong anchor assembly slidably attached to the spine board where a push rod mechanism is used to apply traction force on the skull tong anchor assembly. The push rod mechanism includes a strain gauge device so that the traction force can be selected and monitored. The spine board can also include a mattress that can be attached to the spine board where the mattress includes integrated shoulder straps that can be partially detached therefrom to secure a patient to the spine board.

Abstract: A device for stimulation, the device comprising a hollow body having a first end and a second end, wherein a first connection mechanism is located distal to the first end and the second end has an opening to an interior cavity of the hollow body, a handle attached to the first connection mechanism, a motor positioned within the interior cavity of the hollow body, and a lower panel mechanically secured to the motor, wherein when the motor is activated the lower panel moves in a predetermined pattern.

Abstract: A method is described for treatment of aphthous ulcers or canker sores whereby brief high-pressure vacuum is administered to the aphthous ulcer, resulting in swelling and minor hemorrhage, with immediate relief of pain and hastening of healing of the ulcer.

Abstract: A vibrating back massager with guide slot and vibrating heads is described. The guide slot is designed to restrict lateral movement of the massage device when the guide slot is engaged with a supporting member. The supporting member may be the edge of an open door, a corner, a vertical pole, or other generally available structure. The device includes a strap handle which may be draped over the user's shoulder and used to control the vertical position of the device. The described vibrating massage device allows a single user to create and maintain a significant amount of massage pressure without fatiguing his arms or relying on a second person. In a preferred embodiment, the controls for the vibrating massage device are incorporated into the strap handle so that the speed, intensity, and/or temperature may be controlled by the user without repositioning the device.

Abstract: In some embodiments, a blood flow sensor device such as a non-invasive cardiac arrest monitor (NICAM) that uses ultrasound to detect blood flow is used to monitor blood flow during cardiopulmonary resuscitation. One or more gating signal generation devices transmit gating signals to a blood flow monitoring computing device. The blood flow monitoring computing device uses the gating signals to determine time periods during which blood flow information generated by the blood flow sensor device is most likely to be accurate. The blood flow monitoring computing device measures blood flow during the time periods. In some embodiments, the blood flow monitoring computing device presents the measured blood flow to a user. In some embodiments, the blood flow monitoring computing device transmits a command to a chest compression device based on the measured blood flow.

Abstract: The invention, acupressure gloves/cots with attached single/multiple pellets are made of various materials. The materials such as cloth, rubber, leather, latex, neoprene, and knitted wool are used for making the gloves/cots. The pellets are made from stainless steel, 24k gold plated stainless steel, silver, titanium, magnetics, or Vaccaria seeds. The single or multiple pellets will be attached in the distal area on the palm surface of the gloves/cots. These five finger gloves or individual cots (thumb and index finger) can be worn by an individual like any other typical gloves, for the application of pressure on acupressure points for treatment. It provides people an alternative method of receiving acupressure treatment using gloves/cots that can be used anytime and/or anywhere to apply pressure on specific body/ear acupressure points to relieve any corresponding pathological ailments.

Abstract: An auxiliary acupuncture system includes an auxiliary acupuncture system includes a human machine interface, a storage unit and a processing unit. The human machine interface is configured to receive at least one symptom of an illness. The storage unit is configured to store acupoint information. The acupoint information contains a name and a therapeutic function of each of a plurality of acupoints. The plurality of acupoints is divided into a plurality of sets of acupoints. The processing unit is coupled with the human machine interface and the storage unit, retrieves at least one of the plurality of sets of acupoints from the acupoint information which has a therapeutic effect for the at least one symptom of the illness, and displays the at least one of the plurality of sets of acupoints on the human machine interface.

Abstract: A medical device (100) comprises a container receiver unit (110) configured to receive and hold a container (120), wherein the container (120) accommodates a pharmaceutical product (125) and comprises a first communication tag (130) configured to store information regarding the pharmaceutical product (125), a reader unit (140) configured to wirelessly read the information from the first communication tag (130), and a control unit (150) configured to control the medical device (100) based on the information read from the first communication tag (130). The medical device (100) further comprises an opening or a transparent window (165) allowing to at least partially see from the outside the container (120) inserted into the container receiver unit (110), wherein the reader unit (140) comprises a first antenna unit (142, 144), and the container (120) inserted into the container receiver unit (110) is located between (i) the opening or the transparent window (165) and (ii) the first antenna unit (142, 144).

Abstract: A system for freezing, storing, transporting, and thawing biopharmaceutical product, the system including a stationary equipment and one or more movable pallet, each pallet being configured to carry one or more container units, each containing biopharmaceutical product, the stationary equipment including a gas circulating unit configured to cause a circulation of cold gas and/or warm gas, from a pull inlet toward a blow outlet, wherein there is provided at least a first side plenum having one or more gas conveying channel therein, configured to be fluidly coupled to the blow outlet of the gas circulating unit, the first side plenum having a plurality of outlet ports directed toward an interior volume of the pallet, wherein the gas circulates substantially in a horizontal direction in the interior volume of the pallet.

Abstract: Provided is a medication management system comprising; a) seven or more bags with a compartment for placement of pharmaceutical dosage forms, with at least one bag for each day of a week, each bag having a slot that is isolated from the compartment; b) at least seven bands for attaching the bags, each band having a letter and/or Braille representing a different day of the week, the bands configured to go through the slot of the bag and form a loop, each band having a fastener configured to fasten the band in the looped configuration; and c) a handbag for placement of all the bags and the bands; wherein a user had an option to detachably attach one or more bags to the same band.

Abstract: A male-female adapter (21) can be coupled to a hermetically closable connector (1) with external threading (13) and closing plug (6) which can be bored by pressure of a male fitting so as to form a connector (1)—adapter (21) unit which is suitable for using a female fitting. The adapter (21) comprises an external tubular body (22) with an axial extension (24) which can be hooked to the connector (1) in a rotatable and axially slidable manner, an internal tubular body (26) with terminal tangs (27, 37) axially projecting from the extremities of the external tubular body (22), a middle transversal wall (28) which integrally connects the two tubular bodies (22, 26), and two opposite sense threadings (29, 30) formed in internal portions of the external tubular body (22), which threadings are separated by said middle transversal wall (28).

Abstract: A zirconia ceramic material for use in dental applications is provided comprising an yttria-stabilized zirconia material comprising from 4.5 mol % to 5.1 mol % yttria. Optionally, the zirconia ceramic has a coloring agent that may comprise one or more metals selected from terbium (Tb), chromium (Cr), erbium (Er), and cobalt (Co), and further, may, optionally, comprise alumina, which if present may be in an amount from 0 wt % to 0.25 wt %. The zirconia ceramic materials exhibit both enhanced translucency and a flexural strength of at least 800 MPa when fully sintered.

Abstract: The present invention relates to a powder mixture, in particular for the remineralization of teeth, a powder jet device, in particular for application in the field of dentistry, a use of the powder mixture for producing a means for the remineralization of teeth 5 and to a method for the remineralization of teeth, and a use of a powder mixture in a dental apparatus. The powder mixture comprises a deposition powder which is designed to adhere to tooth surfaces.

Abstract: Disclosed are formulations and compositions comprising the formulations made up of at least tea tree oil, peppermint oil, castor oil, aloe, and lanolin. Also disclosed are cleansing wipes comprising a substrate and a cleansing formulation, wherein said cleansing formulation comprises tea tree oil; peppermint oil; castor oil; aloe; and lanolin. Disclosed are cleansing products comprising a sealed package and at least one cleansing wipe. Also disclosed are methods of cleansing skin, refreshing/rejuvenating the user, cooling or resetting the body temperature and exfoliating, smoothing, and softening of the skin.

Abstract: The present disclosure relates to an emulsified liposome composition and a method for preparing the emulsified liposome composition. The emulsified liposome composition includes a phospholipid, wherein the phospholipid includes a phosphatidyl ethanol amine and a phosphatidylcholine, and a weight ratio of the phosphatidyl ethanol amine to the phosphatidylcholine is 3-6:1. Through the emulsified liposome composition of the present disclosure, the liposome has a small particle diameter, so that it can penetrate into the deep layer of the skin quickly and deeply. Through the moisturizing or anti-oxidant active ingredient encapsulated in the emulsified liposome composition, the emulsified liposome composition has skin moisturizing and anti-oxidation effect, and can be widely used in products regarding maintenance, make-up, and sun-checking.

Abstract: Topical personal care compositions containing amino acids and 4-substituted resorcinols for potentiating glutathione synthesis within skin cells. The compositions can be used to improve skin appearance of chronological aging or photoaging, resulting from exposure to UV light/sunlight, or environmental pollutants. The compositions are also useful for attaining even skin color and reducing pigmentation, age spots and discoloration.

Abstract: The present invention relates to a composition for dyeing keratin fibres, in particular keratin fibres such as the hair, comprising: at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof and/or solvates thereof such as hydrates; at least one particular coupler; optionally at least one fatty substance; optionally at least one basifying agent; and optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibres such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention.

Abstract: Skin lightening additives and personal care compositions containing amino acids and nicotinamide compounds. The compositions are useful for attaining even skin color and reducing pigmentation, age spots and discoloration.

Abstract: Disclosed is a personal care composition comprising: (a) a cationic or nonionic surfactant; (b) a high melting point fatty compound having a melting point of from 25° C. to 60° C. (c) a solid organic compound having a water solubility of lower than 25 g per 1 litter water, and having a melting point of exceeding 60° C., and also having a specific A log P; (d) a first liquid oily compound other than a second liquid oily compound, wherein the first liquid oily compound has a water solubility of 10 g per 1 litter water or less, wherein a mixture of all the first liquid oily compounds included in the composition has a di-electric constant of from about 5 to about 10, and wherein the weight ratio of the solid organic compound to the first liquid oily compound is from about 1:1 to about 1:10; and (e) an aqueous carrier, wherein the composition comprises 0.1% or less of a second liquid oily compound having a higher A log P of 7.0 or higher.

Abstract: The present invention relates to clear compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active, a C8-C24 alcohol ester of a carboxylic acid and a pharmaceutically acceptable topical carrier comprising monohydric and, optionally, dihydric alcohols and water.

Abstract: Provided is a hair restoration/growth stimulating agent containing at least one type of flavonoid represented by formula (I) as an active ingredient. Further provided is a hair restoration/growth stimulating agent containing at least one type of phenylpropanoid represented by formula (II) as an active ingredient.

Abstract: Keratin protein filler compositions are provided that include at least one keratin protein derived from human hair. Hair coloring kits are also provided that include at least one keratin protein filler composition and at least one hair colorant composition. Methods of treatment of various hair conditions are also provided.

Abstract: The present invention relates to a hair dyeing process comprising at least one pigment and at least one aqueous dispersion of polyalkene supramolecular polymer with a surfactant system chosen from an anionic surfactant, a cationic surfactant and a non-ionic surfactant.

Abstract: An olaparib oral sustained and controlled release pharmaceutical composition contains an olaparib in an improved dissolution form and a release rate adjusting matrix polymer. The pharmaceutical composition has controllable in-vivo absorption behavior, plasma concentration and PARP enzyme inhibition level, and improved drug load and/or oral absorption and/or bioavailability and/or plasma concentration control and/or enzyme inhibition level control of olaparib, and can be used as the only preparation or in combination with other therapies to treat a cancer.

Abstract: Methods of preparing inhalable supplements are disclosed. The methods involve aerosolizing a liquid comprising a carrier and a supplement by heating the liquid to a temperature that retains the bioavailability of the supplement. Also disclosed are methods and kits for treating a subject with an inhalable supplement.

Abstract: The present invention relates to an improved kit for preparing injectable carmustine solutions, methods of preparing and administering such solutions, and methods of treatment with such solutions. The kit includes a product vial containing lyophilised carmustine and a diluent vial containing an ethanol-free non-aqueous diluent. Reconstitution of the lyophilised carmustine in the ethanol-free non-aqueous diluent results in a carmustine solution with improved solubility and stability.

Abstract: Disclosed is a method for producing a porous orodispersible film, having the following steps: i) forming a suspension of a pharmaceutically acceptable solvent, a pharmaceutically acceptable matrix material, and a pharmaceutically acceptable binder, said solvent being selected such that the pharmaceutically acceptable matrix material substantially does not dissolve in it, whereas the pharmaceutically acceptable binder is dissolved in the solvent, ii) casting the suspension onto a neutral support, thereby forming a wet film, and iii) drying the wet film and obtaining a dry film. The films produced in this manner have a closed surface on the lower face whereas the upper face is porous, thereby allowing the application of a pharmaceutically active ingredient in the form of a suspension or a solution for example.

Abstract: An oral soluble film contains at least one active agent. Alternatively, a multi-layered film includes a plurality of layers, at least one at least one of the plurality of layers being an oral soluble film layer containing at least one active agent. The oral soluble film may be made, e.g., by a method comprising providing a well of a predetermined size; depositing a film forming composition in the well; metering a predetermined amount of an active agent composition in the well separately from the film forming composition, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming a single layer in the well; and drying the single layer in the well to form the oral soluble film containing the at least one active agent.

Abstract: The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.

Abstract: A formulation for topical application to humans includes an emulsion of micelles in a lipid phase dispersed in an aqueous phase. Each micelle has cannabidiol (CBD) oil and at least one surfactant, and each micelle has a diameter less than about 100 nanometers, and preferably less than 10 nanometers. The CBD oil is present in a range of 3 mg to 100 mg per fluid ounce (30 ml) of emulsion. The aqueous phase includes a mixture of water and polyols or alcohols. The formulation is made by mixing the surfactant and cannabidiol (CBD) oil in a disperse phase, mixing an aqueous phase comprising the water and polyols or alcohols, heating the disperse phase and aqueous phase to about 80 degrees centigrade, slowly transferring the disperse phase into the aqueous phase with moderate sheer and agitation to form the emulsion; and cooling the emulsion to less than 50 degrees centigrade while maintaining a slow to moderate mixing speed.

Abstract: Nitric oxide levels in the blood stream are maintained while delivering, in sustained release, medication or therapeutic agent such as an NSAID (e.g. aspirin). This is accomplished by processing, at room temperature or in a low pressure environment without degradation, an amino acid ester with a nitric acid releasing group in an ethyl cellulose-based or other sustained release polymer delivery system. In this manner, in the blood stream nitric oxide levels are maintained at a level to only produce normotension because the nitric oxide is released only during hypertensive moments. The level of nitric oxide release metabolites reaches significance and physiological relevance anywhere between 12 and 48 hours depending upon the individual being dosed level of activity, ambient systolic blood pressure and numerous other factors that create the hypertensive environment that releases nitric oxide from the nitric oxide releasing amino acid ester.

Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.

Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

Abstract: Cannabis products and industrial methods for production thereof. A homogeneous composition comprising cannabinoid-containing comminuted cannabis plant material, where at least 70 weight % of the comminuted cannabis plant material is of a size greater than 0.3 millimeter and less than 4.2 millimeters; the composition comprises at least 1% by weight moisture and less than 20% by weight moisture; and the cannabinoid concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the cannabinoid concentration in a separate 1 gram fraction of said 10 gram sample.

Abstract: Systems, apparatus, and methods for combining a sugar-based solution, such as maple syrup, and cannabinoids are provided, in which a method, for instance, may comprise creating maple syrup and separately warming the maple syrup and a cannabinoid concentrate to a first temperature and combining them to create a mixture. The method also may comprise applying a bottom heat source and/or a top radiant heat source to the mixture and increasing the mixture's temperature to a second temperature sufficient to initiate crystallization, while stirring at a first RPM set point. The method also comprises discontinuing, upon the mixture reaching full crystallization, the heating and stirring RPMs. A method for creating an orally dissolvable tablet is also provided, comprising taking the combined cannabinoids and maple syrup in powder form, mixing with a secondary formulation and an excipient mixture, and pressing the resulting mixture into tablet form.

Abstract: Embodiments provide swallowable devices, preparations and methods for delivering viable cells (VC) into the GI tract including GI wall tissue or other tissue site. Particular embodiments provide a swallowable device such as a capsule for delivering VC into an intestinal wall or other site. The VC can be contained within a tissue-penetrating shell disposed in the capsule that protects the VC as they pass through the GI tract until they are inserted into GI tract tissue or other location. The shell desirably has shape, size and material consistency to be contained in a swallowable capsule, delivered from the capsule into solid tissue by the application of force on the shell and biodegrade within the solid tissue to release the VC into the tissue. Within the shell or other structure the VC can be maintained in a viability-sustaining gel that preserves the viability of the VC for selected time periods.

Abstract: The present disclosure relates to microcapsules, methods of using such microcapsules in the delivery of drugs and probiotic microbes to subjects in need thereof, and methods of using such microcapsules for in vitro culture of microbes. In particular, the microcapsules comprise novel siloxane-based membranes that maintains transport properties essential to communication and growth of microbes.

Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.

Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.

Abstract: The present invention provides a risperidone-containing patch having an excellent drug release property and patch physical properties. Specifically, the present invention provides a medical patch comprising an adhesive composition comprising risperidone or a pharmaceutically acceptable salt thereof; a carboxylic acid; a fatty acid ester; and an adhesive, characterized in that said adhesive is a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a sulfur residue of a mercapto group situated at the center, wherein the (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.99% by mass of the whole structural units in said star-shaped acrylic block polymer, and at least one of said chain polymer portions has a structural unit having a copolymer structure of polymerizable monomers comprising a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a polyfunctional monomer.

Abstract: The present disclosure relates to compositions methods of use and methods of manufacturing, hydrous hydrogel compositions useful as topical oral analgesics including cannabinoids and menthol.

Abstract: Aqueous solution, comprising, in dissolved state,—at least one stilbenoid—at least one saccharide, and method for increasing the solubility in water.

Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).

Abstract: A therapeutic dosage form includes a pharmaceutically active ingredient, a crosslinked polyacid, and a linear polyacids. The crosslinked polyacid is insoluble in water, and the linear polyacid is soluble in water. An example of a crosslinked polyacids is sodium carboxymethylcellulose. The linear polyacid possesses sufficient binding sites to form a stable complex with the pharmaceutically active ingredient. An example of a linear polyacid is polymethacrylic acid. The ingredients are formed into a tablet or capsule, either admixed, in layers, or separated by a coating. Abuse is deterred in that crushing causes the active ingredient to be bound and not abusable, and placing the dosage in solution causes a strong complex to be formed between the polyacid and the active ingredient, including a solution with ethanol.

Abstract: A system for inducing weight loss in an individual includes a collection having plurality of dose units therein. Each dose unit includes a first dose of phentermine or a second dose of phentermine. The first dose is greater than the second dose, and the collection includes at least one first dose and at least one second dose.

Abstract: Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of albuterol and a therapeutically effective amount of hypertonic saline. Also provided here are methods of using the aforementioned pharmaceutical compositions to treat one or more symptoms of obstructive airway diseases.

Abstract: Viability of cancer cells (e.g., glioblastoma cells) can be reduced by administering ABT-751 to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz (e.g., 200 kHz) to the cancer cells. Notably, experiments show that the combination of ABT-751 and the alternating electric field produces synergistic results for certain glioblastoma cell lines.

Abstract: The present invention provides the use of isoferulic acid, Chinese medicine extracts containing isoferulic acid, and Cimicifugae rhizoma in the preparation of a medicine or a functional health product for autoimmune diseases. The present invention provides new uses for isoferulic acid, Chinese medicine extracts containing isoferulic acid, pharmaceutical compositions, traditional Chinese medicine compositions, etc., and develops the application field of drugs or functional health products for autoimmune diseases. The raw materials are widely available, the cost is low, and it has broad market application value.

Abstract: A method of treating or preventing a bacterial infection in the lung of a subject by administering an inhaled antibiotic, and at least 37.5 mg/day of an inhaled chelating agent, each in one or more doses, wherein the or each dose of the chelating agent and/or antibiotic is administered over a period of no more than 8h.